TY - JOUR
T1 - Prevention of β‐Lactam‐Associated Diarrhea by Saccharomyces boulardii Compared with Placebo
AU - McFarland, Lynne V.
AU - Surawicz, Christina M.
AU - Greenberg, Richard N.
AU - Elmer, Gary W.
AU - Moyer, Kris A.
AU - Meicher, Sally A.
AU - Bowen, Karen E.
AU - Cox, Jenny L.
PY - 1995/3
Y1 - 1995/3
N2 - Objectives: To determine the safety and efficacy of a new preventive agent for antibiotic‐associated diarrhea (AAD) in patients receiving at least one β‐lactam antibiotic. Methods: A double‐blinded, placebo‐controlled, parallel group study was performed in a high‐risk group of hospitalized patients receiving a new prescription for a β‐lactam antibiotic and having no acute diarrhea on enrollment. Lyophilized Saccharomyces bonlardii or placebo (1 g/day) was given within 72 h of the start of the antibiotic(s) and continued until 3 days after the antibiotic was discontinued, after which the patients were followed for 7 wk. Results: Of the 193 eligible patients, significantly fewer, 7/97 (7.2%), patients receiving S. boulardii developed AAD compared with 14/96 (14.6%) on placebo (p= 0.02). The efficacy of S. boulardii for the prevention of AAD was 51%. Using a multivariate model to adjust for two independent risk factors for AAD (age and days of cephalosporin use), the adjusted relative risk was significantly protective for S. boulardii (RR = 0.29, 95% C1 = 0.08, 0.98). Conclusion: The prophylactic use of S. boulardii given with a β‐lactum antibiotic resulted in a significant reduction of AAD with no serious adverse reactions.
AB - Objectives: To determine the safety and efficacy of a new preventive agent for antibiotic‐associated diarrhea (AAD) in patients receiving at least one β‐lactam antibiotic. Methods: A double‐blinded, placebo‐controlled, parallel group study was performed in a high‐risk group of hospitalized patients receiving a new prescription for a β‐lactam antibiotic and having no acute diarrhea on enrollment. Lyophilized Saccharomyces bonlardii or placebo (1 g/day) was given within 72 h of the start of the antibiotic(s) and continued until 3 days after the antibiotic was discontinued, after which the patients were followed for 7 wk. Results: Of the 193 eligible patients, significantly fewer, 7/97 (7.2%), patients receiving S. boulardii developed AAD compared with 14/96 (14.6%) on placebo (p= 0.02). The efficacy of S. boulardii for the prevention of AAD was 51%. Using a multivariate model to adjust for two independent risk factors for AAD (age and days of cephalosporin use), the adjusted relative risk was significantly protective for S. boulardii (RR = 0.29, 95% C1 = 0.08, 0.98). Conclusion: The prophylactic use of S. boulardii given with a β‐lactum antibiotic resulted in a significant reduction of AAD with no serious adverse reactions.
UR - http://www.scopus.com/inward/record.url?scp=0028985777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028985777&partnerID=8YFLogxK
U2 - 10.1111/j.1572-0241.1995.tb08241.x
DO - 10.1111/j.1572-0241.1995.tb08241.x
M3 - Article
C2 - 7872284
AN - SCOPUS:0028985777
VL - 90
SP - 439
EP - 448
IS - 3
ER -
